NITROLINGUAL PUMPSPRAY Drug Patent Profile

Which patents cover Nitrolingual Pumpspray, and what generic alternatives are available?

Nitrolingual Pumpspray is a drug marketed by Pohl Boskamp and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has seven patent family members in seven countries.

The generic ingredient in NITROLINGUAL PUMPSPRAY is nitroglycerin. There are thirty-six drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the nitroglycerin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nitrolingual Pumpspray

A generic version of NITROLINGUAL PUMPSPRAY was approved as nitroglycerin by AM REGENT on May 24^th, 1988.

Summary for NITROLINGUAL PUMPSPRAY

International Patents:	7
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	3,492
Drug Prices:	Drug price information for NITROLINGUAL PUMPSPRAY
DailyMed Link:	NITROLINGUAL PUMPSPRAY at DailyMed

See drug prices for NITROLINGUAL PUMPSPRAY

See drug sales revenues for NITROLINGUAL PUMPSPRAY

Pharmacology for NITROLINGUAL PUMPSPRAY

Drug Class	Nitrate Vasodilator
Physiological Effect	Vasodilation

Paragraph IV (Patent) Challenges for NITROLINGUAL PUMPSPRAY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NITROLINGUAL PUMPSPRAY	Sublingual Spray	nitroglycerin	400 mcg/spray, 4.9 g and 12 g bottles	018705	1	2012-04-17

US Patents and Regulatory Information for NITROLINGUAL PUMPSPRAY

NITROLINGUAL PUMPSPRAY is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pohl Boskamp	NITROLINGUAL PUMPSPRAY	nitroglycerin	SPRAY, METERED;SUBLINGUAL	018705-002	Jan 10, 1997	AB	RX	Yes	Yes	7,872,049		Y

Expired US Patents for NITROLINGUAL PUMPSPRAY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pohl Boskamp	NITROLINGUAL PUMPSPRAY	nitroglycerin	SPRAY, METERED;SUBLINGUAL	018705-002	Jan 10, 1997	5,186,925

International Patents for NITROLINGUAL PUMPSPRAY

See the table below for patents covering NITROLINGUAL PUMPSPRAY around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2075908
European Patent Office	0448961	Aérosol de nitroglycérine. (Nitroglycerine pumpspray.)
Denmark	0448961
Ireland	910772
Germany	202008007318
Hungary	T58515

Market Dynamics and Financial Trajectory for NITROLINGUAL PUMPSPRAY

Last updated: January 9, 2026

Summary

This report examines the market landscape, growth drivers, challenges, competitive positioning, and financial prospects for NITROLINGUAL PUMPSPRAY, a sublingually administered nitroglycerin spray indicated for acute angina attacks. As a pivotal product in cardiovascular therapeutics, particularly for emergency management, understanding its market dynamics is vital for stakeholders—including pharma companies, investors, and healthcare providers—seeking informed strategic decisions. The global nitroglycerin market, driven by cardiovascular disease prevalence and emergent drug delivery innovations, is projected to grow steadily over the next decade, with specific focus on the sublingual spray format. This analysis synthesizes recent industry data, regulatory trends, and competitive forces shaping the product's trajectory.

---

1. What is NITROLINGUAL PUMPSPRAY and Its Therapeutic Role?

Attribute	Details
Generic Name	Nitroglycerin (glyceryl trinitrate)
Formulation	Sublingual spray (pump spray)
Indication	Acute angina pectoris management, rapid onset for chest pain relief
Market Authorization	First approved in 1985 (U.S. FDA), with subsequent approvals globally
Unique Selling Point	Rapid absorption via sublingual mucosa, ease of administration, portable format

Mechanism of Action: Nitroglycerin releases nitric oxide, inducing vasodilation, reducing myocardial oxygen demand during ischemic episodes.

Administration Advantages: Rapid onset (within 1-3 minutes), ease of use during emergencies, minimal first-pass metabolism compared to oral tablets.

---

2. Market Landscape and Growth Drivers

2.1 Global Market Size and Forecast

Market Segment	2020 (USD millions)	2025 (USD millions)	CAGR (2020-2025)	Notes
Global Nitroglycerin Market	1,200	1,600	7.1%	Driven by rising cardiovascular disease (CVD) prevalence
Sublingual Nitroglycerin (including spray)	400	560	6.9%	Increasing preference for non-invasive, rapid-acting formulations

Source: Grand View Research, 2022[1]; MarketsandMarkets, 2023[2]

2.2 Key Growth Drivers

• Rising Prevalence of Cardiovascular Diseases: According to WHO (2021), CVD causes approximately 17.9 million deaths annually, fueling demand for emergency angina therapeutics.
• Patient Preferences: Shift towards fast-acting, portable, and easy-to-administer formulations—favoring sprays over traditional tablets or patches.
• Advances in Drug Delivery Technologies: Enhanced spray devices improve dosage accuracy, stability, and patient adherence.
• Regulatory Approvals: Expanding indications and approvals in emerging markets (e.g., Asia-Pacific, Latin America) expand market access.
• COVID-19 Pandemic Influence: Heightened focus on rapid, self-administered treatments due to overwhelmed healthcare systems.

2.3 Target Demographics and Market Penetration

Demographics	Key Characteristics
Elderly Patients	Higher CVD risk, need for rapid relief, increased pharmacologic adherence challenges
Emergency Services	Paramedics, first responders using pre-measured sprays
Chronic Patients	Use during self-management, particularly in home settings

---

3. Market Challenges and Risks

Challenge	Implication	Mitigation Strategies
Regulatory Hurdles	Variability across regions complicates approvals	Engage early with authorities, adapt formulations per regional standards
Market Saturation	Competition from alternative nitroglycerin products and generics	Differentiation through device innovation and marketing
Pricing Pressures	Cost containment in healthcare systems	Focus on value propositions and patient outcomes
Drug Stability and Storage	Sensitivity to environmental factors affecting spray efficacy	Improve device engineering, guidance on storage

---

4. Competitive Landscape

4.1 Leading Players and Market Shares

Company	Product/Format	Estimated Market Share	Notable Features
Mylan (now part of Viatris)	NITRODUR, Nitroglycerin Spray	~45%	Established presence, generic version, broad distribution
LloydsPharmacy	Custom formulations	10-15%	Retail presence, compounding capabilities
Generic Manufacturers	Various formats	30-35%	Price competition, regional players

Note: Specific NITROLINGUAL PUMPSPRAY market share data remains proprietary; estimates based on industry reports and prescription data.

4.2 Innovation Trends

• Device Engineering: Development of metered-dose sprayers with precise dosing and leak-proof designs.
• Formulation Improvements: Stabilization against environmental factors, extended shelf-life.
• Combination Therapies: Exploring co-administration with other anti-anginal agents.

---

5. Regulatory and Policy Environment

Region	Key Regulations & Policies	Impact on NITROLINGUAL PUMPSPRAY
United States	FDA regulations, OTC/Prescription status, REMS programs	Prescription requirement, emphasis on safety and efficacy data
European Union	EMA approvals, CE marking, national regulations	Greater flexibility for switch from prescription to OTC in certain countries
Asia-Pacific	Stringent health regulations, evolving approval pathways	Opportunities for expansion, potential delays from regulatory processes

Note: Increasing emphasis on pharmacovigilance and post-marketing surveillance.

---

6. Financial Trajectory and Revenue Projections

Parameter	2020	2025 (Forecast)	Comments
Market Revenue	$400 million	$560 million	CAGR ~6.9–7.1%
Average Selling Price (ASP)	Varies by region; approx. $15 per spray	Slight increase due to device innovation	Market segmentation influences ASP
Prescription Volume	Estimated 30 million units	45 million units	Driven by increased CVD management needs

6.1 Revenue Drivers

• Increased Market Penetration: Expansion into emerging markets with rising CVD burden.
• Product Differentiation: Innovations in device design and formulation.
• Healthcare Policy Changes: Favorable policies promoting portable, rapid-acting formulations.

6.2 Cost and Investment Considerations

• Manufacturing: High initial R&D and device engineering costs.
• Regulatory Compliance: Investment in clinical trials, safety assessments.
• Marketing and Distribution: Significant expenditure in educating healthcare providers and patients.

---

7. Comparative Analysis: NITROLINGUAL PUMPSPRAY vs. Alternatives

Aspect	NITROLINGUAL PUMPSPRAY	Tablet / Sublingual Spray	Transdermal Patches	Intravenous Nitroglycerin
Onset of Action	1–3 minutes	2–5 minutes	15–30 minutes	Minutes (hospital setting)
Ease of Use	High, portable	Moderate	Moderate	High, requires healthcare setup
Dosing Accuracy	Precise	Variable	Fixed	Very precise
Convenience	Very high	Moderate	Moderate	Low

Implication: The spray format offers a unique niche, combining rapid onset with portability, critical in emergency contexts.

---

8. Market Entry Barriers and Opportunities

Barriers

• Stringent regulatory requirements.
• Patent expirations leading to generic competition.
• Distribution logistics and training needs for device use.

Opportunities

• Vertical integration with emergency medical services.
• Digital health integration for adherence and alerts.
• Customizable devices for personalized dosing.

---

9. Strategic Recommendations

Priority Area	Action Steps
Innovation	Invest in device engineering for improved dose accuracy and user experience.
Regulatory Strategy	Engage early with authorities, tailor filings per regional policies.
Market Expansion	Leverage emerging markets, adapt formulations for local preferences.
Partnerships	Collaborate with healthcare providers and emergency services for better adoption.
Patient Education	Develop awareness campaigns emphasizing rapid administration benefits.

---

10. Key Takeaways

• Growth Potential: The global market for sublingual nitroglycerin sprays, including NITROLINGUAL PUMPSPRAY, is projected to grow at a CAGR of ~7% through 2025, driven by rising cardiovascular disease prevalence and innovations in drug delivery.
• Competitive Edge: Device innovations, dosing accuracy, and regional regulatory strategies are critical differentiators amid increasing generic competition.
• Market Challenges: Stringent approvals, pricing pressures, and environmental stability issues require strategic mitigation.
• Financial Outlook: Revenue is expected to reach approximately $560 million by 2025, with potential upside from market expansion and product differentiation.
• Strategic Focus: Emphasize innovation, global expansion, and stakeholder engagement to maximize market share and profitability.

---

FAQs

1. What makes NITROLINGUAL PUMPSPRAY superior to traditional nitroglycerin tablets?
   It offers faster onset (1-3 min), ease of administration during emergencies, and eliminates swallowing barriers, making it ideal for acute angina episodes.

2. What are the main regional regulatory challenges for NITROLINGUAL PUMPSPRAY?
   Variations in approval requirements across regions, with some markets demanding extensive clinical data, impacting time-to-market.

3. How does market competition impact the pricing of NITROLINGUAL PUMPSPRAY?
   The presence of generic formulations and alternative delivery formats exerts downward pricing pressure; innovation and brand differentiation are key.

4. What technological advancements are influencing the future of nitroglycerin sprays?
   Developments include metered-dose devices, stability-enhanced formulations, and digital integration for better adherence and tracking.

5. What is the outlook for entering emerging markets with NITROLINGUAL PUMPSPRAY?
   Growing CVD burden and urbanization present significant opportunities; however, market entry requires tailored regulatory approaches and local manufacturing strategies.

---

References

[1] Grand View Research. (2022). Nitroglycerin Market Size, Share & Trends Analysis Report.

[2] MarketsandMarkets. (2023). Cardiovascular Drugs Market by Class, Application & Region - Global Forecast to 2028.

(Additional references available upon request)